My research investigates the epigenetic landscape surrounding T-cell lineage restriction in normal and leukemic T-cell development by using our lab’s well-established cord blood transduction protocols, genomic assays, and spectral flow cytometry. We hope to understand how the aberrant expression of epigenetic modifiers (e.g. DNMT3A) can contribute to the pathogenesis of T-ALL, particularly in subtypes that co-express myeloid markers, such as ETP-ALL.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.